QHDAC

QHDAC is a biotechnology company focused on developing highly selective, next-generation histone deacetylase (HDAC) inhibitors for the treatment of neurodegenerative and inflammatory diseases. The company's proprietary platform enables the design of isoform-selective inhibitors, particularly targeting Class IIa HDACs, which avoids the toxicity associated with broad-spectrum HDAC inhibition. QHDAC's lead programs are currently in the pre-clinical stage, with a primary focus on conditions such as Huntington's disease and other CNS disorders. By leveraging deep expertise in chemical biology and medicinal chemistry, the company aims to unlock the therapeutic potential of HDAC modulation while maintaining a superior safety profile.